Upon joining the study, the patient provides signed informed consent, confirming understanding and agreement to participate.

The patient must be 18 years or older and have a confirmed diagnosis of ulcerative pyoderma gangrenosum, with a PARACELSUS score of 10 points or more.

The patient undergoes an initial assessment to confirm the presence of at least one evaluable ulcer, which must be at least 5 cm² in area and surrounded by intact skin.

The ulcer is evaluated using two-dimensional measurements to establish a baseline for the study.

The patient receives treatment with either vilobelimab or a placebo. The specific dosage and frequency are determined by the study protocol.

The treatment aims to achieve complete closure of the target ulcer, defined as re-epithelization without drainage or dressing needs, confirmed at two consecutive visits two weeks apart.

Throughout the study, the patient attends regular visits for assessments of ulcer healing, pain levels, and any changes in condition.

Pain reduction is measured using a numeric rating scale from 0 to 10, with specific goals for reduction set at various points in the study.

At the end of the treatment phase, the patient undergoes a final evaluation to assess the overall effectiveness of the treatment.

The primary goal is the complete closure of the target ulcer, while secondary goals include pain reduction and ulcer volume reduction.